Impact of a Novel Dehydroepiandrosterone Derivative on the Metabolism of RWPE-1 and LNCaP Cell Lines

June 2026 in “ Oriental Journal Of Chemistry ”

Marisa Cabeza, Karla Mejía, Yvonne Heuze, Miguel Morales-Pacheco, Mauricio Rodríguez‐Dorantes

dehydroepiandrosterone steroid 12 testosterone dihydrotestosterone finasteride dutasteride RWPE-1 LNCaP prostate cancer DHEA Propecia Avodart

From the encyclopedia

dehydroepiandrosterone →

Finasteride →

Frontline, gold standard treatment for combatting androgenic alopecia

Dutasteride →

Heavy duty finasteride that comes with higher risks

Studysummary This research found that a novel dehydroepiandrosterone derivative (12) significantly reduces cell viability and increases apoptosis in testosterone-stimulated normal and tumor prostate cells, unlike finasteride and dutasteride, which also showed activity under dihydrotestosterone stimulation.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on orientjchem.org →

Discuss this study in the Community →

Research cited in this study

5 / 5 results

research Novel Type 1 5a-Reductase Inhibitors With Antiproliferative Potential On LNCaP Cells

June 2023 in “Oriental Journal of Chemistry/Oriental journal of chemistry”

This study demonstrated that derivatives of dehydroepiandrosterone (2a-b, 3a-f, and 4a-f) significantly reduced viable LNCaP prostate cancer cells, suggesting potential therapeutic use for metastatic prostate cancer, while finasteride did not alter cell viability.

research The Direct Inhibitory Effect of Dutasteride or Finasteride on Androgen Receptor Activity Is Cell Line Specific

12 citations , June 2013 in “The Prostate”

This study found that dutasteride more effectively inhibited androgen receptor signaling and reduced cell growth compared to finasteride in prostate cancer cell models, with varying sensitivities across different cell lines.

research The Antiandrogenic Effect of Finasteride Against a Mutant Androgen Receptor

20 citations , May 2011 in “Cancer Biology & Therapy”

This study found that finasteride decreased DHT-stimulated AR activity and cell growth in prostate cancer cells with mutant AR, but not in those with wild type AR.

research Differential Expression of Steroid 5α-Reductase Isozymes and Association with Disease Severity and Angiogenic Genes Predict Their Biological Role in Prostate Cancer

30 citations , June 2010 in “Endocrine Related Cancer”

In this study, dutasteride more effectively reduced prostate cancer cell viability than finasteride in vitro, but did not significantly alter the angiogenic response.

Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor

research Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor

136 citations , March 1996 in “Journal of the American Chemical Society”

This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.